Elsevier Announces Title Change and New Editor-In-Chief for Cancer Genetics and Cytogenetics Journal

By Elsevier, PRNE
Sunday, December 5, 2010

First issue of Cancer Genetics under editorial leadership of Dr. Jaclyn A. Biegel to be published January 2011

OXFORD, England, December 6, 2010 - Elsevier, the world's leading publisher of scientific, technical and
medical information, announced today that its highly respected Cancer
Genetics and Cytogenetics journal is changing its title to Cancer Genetics
and has named Dr. Jaclyn A. Biegel as editor-in-chief.

The changes reflect broader aims and scope for the journal, with a new
focus on diagnostic applications as well as the genetic predisposition of
cancer, and mark an important move by Elsevier to provide the STM community
with a wider variety of original, clinically relevant information for the
diagnosis, prognosis and risk evaluation of cancer patients and a greater
understanding of how altered gene regulation will ultimately lead to new,
targeted therapies for treatment. The first issue of Cancer Genetics will be
published in January 2011, with a new cover and interior design.

Journal Editor-in-Chief Dr. Jaclyn A. Biegel, said, "In addition to
papers on the cellular, genetic and molecular aspects of cancer, I look
forward to publishing a greater number of articles in the areas of genetic
predisposition to cancer, personalized medicine, and new diagnostic
approaches. We [also] welcome the submission of classical
cytogenetic reports."

"This is an extraordinary time to work in the field of cancer genetics,
as we continue to elucidate
the genetic etiology of the many different diseases we call cancer, and
enter the era of personalized medicine. In the coming years, we hope to
address all of these aspects of cancer research, from gene discovery to risk
assessment and treatment, in Cancer Genetics," she added.

Editor-in-Chief Dr. Jaclyn A. Biegel is the Director of the Cancer
Cytogenetics Laboratory at the Children's Hospital of Philadelphia and a
Professor of Pediatrics at the University of Pennsylvania School of Medicine.
Her clinical expertise is in the diagnosis of pediatric leukemia and solid
tumors, and her research expertise is in the genetics of pediatric brain
tumors and rhabdoid tumors.

About Cancer Genetics

Cancer Genetics (www.cancergeneticsjournal.org/), formerly Cancer
Genetics and Cytogenetics, is published 12 times a year. It has been
published continuously since 1979, a time when cancer cytogenetics was just
emerging as a discipline, and investigators in pathology, oncology and
genetics were only beginning to assess the genetic basis for hematologic
malignancies and solid tumors.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com/) and Cell (
www.cell.com/), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com/), SciVerse Scopus
(www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD
Consult (www.mdconsult.com/php/229216853-2/homepage) and Nursing
Consult (www.nursingconsult.com/php/229216862-2/home.html), which
enhance the productivity of science and health professionals, and the SciVal
suite (www.scival.com/) and MEDai's Pinpoint Review (
www.medai.com/), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC (
www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and
information provider, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact
    Mustak Kothia

Media Contact: Mustak Kothia, +44(0)20-7424-4404, m.kothia at elsevier.com

will not be displayed